Review
Immunology
Xiaomin Zhang, Lingling Zhu, Hui Zhang, Shanshan Chen, Yang Xiao
Summary: CAR-T cell therapy has shown significant success in the treatment of hematological malignancies, but challenges remain in terms of adverse events and resistance mechanisms.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Manasi P. Jogalekar, Ramya Lakshmi Rajendran, Fatima Khan, Crismita Dmello, Prakash Gangadaran, Byeong-Cheol Ahn
Summary: CAR-T cell therapy is a promising immune cell therapy for cancer, showing remarkable clinical responses in B-cell leukemia or lymphoma. However, it still faces challenges in treating other hematological and solid tumor malignancies, including severe toxicities and limited anti-tumor efficacy. This review discusses innovative CAR T-cell strategies to improve treatment outcomes and addresses the current challenges and new developments in CAR T-cell therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Anqi Ren, Xiqin Tong, Na Xu, Tongcun Zhang, Fuling Zhou, Haichuan Zhu
Summary: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with high relapse rates and poor prognosis. Current guidelines do not recommend specific treatments, and allogeneic stem cell transplant is the only curative therapy with potential risks. Recent trials have shown success in treating hematologic malignancies with immunotherapies such as monoclonal antibodies, checkpoint inhibitors, and CAR T therapies. However, developing CAR T immunotherapy for T-ALL is challenging due to potential risks of fratricide, T-cell aplasia, immunosuppression, and product contamination.
Article
Oncology
Behnia Akbari, Zahra Hosseini, Pardis Shahabinejad, Saba Ghassemi, Hamid Reza Mirzaei, Roddy S. O'Connor
Summary: This article focuses on the functional impairments of CAR T cells in tumor microenvironments, where tumor cell metabolism and nutrient competition affect the differentiation and function of CAR T cells' progeny. Metabolic intermediates shape the immune response by influencing epigenetic programs.
Review
Cell & Tissue Engineering
Faroogh Marofi, Roza Motavalli, Vladimir A. Safonov, Lakshmi Thangavelu, Alexei Valerievich Yumashev, Markov Alexander, Navid Shomali, Max Stanley Chartrand, Yashwant Pathak, Mostafa Jarahian, Sepideh Izadi, Ali Hassanzadeh, Naghmeh Shirafkan, Safa Tahmasebi, Farhad Motavalli Khiavi
Summary: CAR T cells have shown significant advancements in treating blood disorders, but face challenges in solid tumor therapy due to issues with recognition, trafficking, and survival within the tumor. Efforts to overcome these challenges, including addressing the immunosuppressive tumor microenvironment, show promise in reducing T cell exhaustion and improving therapeutic outcomes in non-hematologic malignancies.
STEM CELL RESEARCH & THERAPY
(2021)
Review
Oncology
Ali Hosseini Rad S. M., Joshua Colin Halpin, Mojtaba Mollaei, Samuel W. J. Smith Bell, Nattiya Hirankarn, Alexander D. McLellan
Summary: CAR T-cell therapy has shown impressive therapeutic outcomes in some haematological malignancies, but has consistently failed in treating solid tumors in clinical settings. Evidence indicates the importance of mitochondrial and metabolic state of CAR T cells prior to infusion, with reprogramming metabolism as a viable approach to enhance antitumor functions and longevity in the nutrient-restricted tumor microenvironment.
Review
Cell Biology
Clement Yisai Wang, Stephanie Po Ting Cheung, Ryohichi Sugimura
Summary: Chimeric antigen receptor (CAR) T cells (CAR-T) are a significant personalized anticancer treatment strategy that can bind to tumor-specific antigens and exhibit antitumor abilities. However, the challenges of antigen escape, tumor infiltration, and other toxic side effects restrict the prolonged usage of CAR-T therapies. Engineering immunology, such as stem cell-based CAR-T therapies and CAR-M (macrophage) therapies, have been developed to overcome the limitations of conventional CAR-T therapies. This review highlights the challenges of CAR-T therapies and the potential of engineering immunology for cancer immunotherapy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Editorial Material
Hematology
Rawan G. Faram, Marco L. Davila
Summary: The CAR-HEMATOTOX predictive model by Rejeski et al in this issue of Blood can identify patients at highest risk of hematologic toxicity following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma.
Review
Medicine, General & Internal
Diana Gumber, Leo D. Wang
Summary: Chimeric antigen receptor (CAR) T cell therapy has shown impressive antitumor activity in the treatment of hematological malignancies, but CAR T cell exhaustion remains a major limitation. This review discusses the underlying mechanisms of exhaustion and emerging strategies to prevent or reverse exhaustion through modifications of the CAR receptor or CAR independent pathways. These strategies hold potential for improving the clinical outcomes of CAR T cell therapy.
Review
Oncology
Xuejia Zhai, Ling Mao, Min Wu, Jie Liu, Shicang Yu
Summary: This article reviews the clinical research status, obstacles, advancements, and challenges of anti-MSLN CAR-T cell therapy, and summarizes strategies to improve its efficacy and safety. Anti-MSLN CAR-T cell therapy is a rapidly developing immunotherapy that has shown high safety but limited efficacy in clinical trials. Current approaches to enhance the proliferation and persistence of anti-MSLN CAR-T cells include local administration and the introduction of new modifications.
Review
Immunology
Haolong Lin, Jiali Cheng, Wei Mu, Jianfeng Zhou, Li Zhu
Summary: CAR-T cell therapy has shown remarkable success in antitumor treatments, particularly against hematological malignancies. The development of universal CAR-T (UCAR-T) cell therapy may overcome current limitations, with a focus on safety, efficiency, and potential complementary immune cells. The landscape and prospects of UCAR-T cell therapy are explored through a comprehensive overview of progress and challenges.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Maryam Akhoundi, Mahsa Mohammadi, Seyedeh Saeideh Sahraei, Mohsen Sheykhhasan, Nashmin Fayazi
Summary: CAR T cell therapy has shown great potential in treating hematologic malignancies, but faces challenges in treating solid tumors, including treatment-related toxicity and specificity. In order to enhance the specificity and overcome immunosuppression, strategies to establish a balance between toxicity and activity of CAR T cells are essential for optimizing efficacy.
Review
Pharmacology & Pharmacy
Javad Masoumi, Abdollah Jafarzadeh, Jalal Abdolalizadeh, Haroon Khan, Jeandet Philippe, Hamed Mirzaei, Hamid Reza Mirzaei
Summary: CSCs are cells with self-renewal ability that initiate tumors and are potential targets for novel anticancer therapeutic agents. CAR-T cells, engineered T cells expressing an artificial receptor specific for TAAs, have shown higher efficiency in cancer treatment by accurately targeting and killing cancer cells.
ACTA PHARMACEUTICA SINICA B
(2021)
Review
Pharmacology & Pharmacy
Hassan Dana, Ghanbar Mahmoodi Chalbatani, Seyed Amir Jalali, Hamid Reza Mirzaei, Stephan A. Grupp, Eloah Rabello Suarez, Catarina Raposo, Thomas J. Webster
Summary: New approaches in cancer immunotherapy, such as checkpoint inhibitors for solid tumors and CAR-T cell therapy for hematologic malignancies, have shown promising results. While CAR-T products have demonstrated powerful effects against B cell cancers, challenges exist in using them for solid tumors.
ACTA PHARMACEUTICA SINICA B
(2021)
Review
Immunology
Wendy Mao
Summary: The antitumor potential of personalized immunotherapy, including adoptive T-Cell therapy, has been shown in both preclinical and clinical studies. Combining cell therapy with targeted metabolic interventions can further enhance therapeutic outcomes. Research has found that metabolic reprogramming can increase T cell proliferation, survival, and anti-tumor cytotoxicity, improving the antitumor potential of T cell therapy and finding ways to improve the success rate of cell transplantation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Chen-Yen Kuo, Cheng-Lung Ku, Hye-Kyung Lim, Shao-Hsuan Hsia, Jainn-Jim Lin, Chia-Chi Lo, Jing-Ya Ding, Rei-Lin Kuo, Jean-Laurent Casanova, Shen-Ying Zhang, Luan-Yin Chang, Tzou-Yien Lin
Summary: This study suggests that mutations in the TLR3 gene may be associated with EV71 encephalitis in children. TLR3-deficiency leads to increased susceptibility to EV71 infection, and this may contribute to the severity of the infection.
JOURNAL OF CLINICAL IMMUNOLOGY
(2022)
Article
Immunology
Yi-Chun Chen, Shao-Wen Weng, Jing-Ya Ding, Chen-Hsiang Lee, Cheng-Lung Ku, Wen-Chi Huang, Huey-Ling You, Wan-Ting Huang
Summary: Patients with anti-IFN-gamma antibodies exhibit immune dysfunction, with T cell exhaustion and adaptive NK cells leading to specific clinical and pathological features.
JOURNAL OF CLINICAL IMMUNOLOGY
(2022)
Correction
Immunology
Chen-Yen Kuo, Cheng-Lung Ku, Hye-Kyung Lim, Shao-Hsuan Hsia, Jainn-Jim Lin, Chia-Chi Lo, Jing-Ya Ding, Rei-Lin Kuo, Jean-Laurent Casanova, Shen-Ying Zhang, Luan-Yin Chang, Tzou-Yien Lin
JOURNAL OF CLINICAL IMMUNOLOGY
(2022)
Review
Cell Biology
Kung-Chi Kao, Stefania Vilbois, Chin-Hsien Tsai, Ping-Chih Ho
Summary: The metabolically hostile tumour microenvironment can hinder immune cells and impede the effectiveness of immunotherapy. Metabolic communication between cancer cells and immune cells may play a crucial role in determining immune responses. Nutrient-limiting strategies may enhance anti-tumour immune responses.
NATURE CELL BIOLOGY
(2022)
Review
Oncology
Jaeoh Park, Limei Wang, Ping-Chih Ho
Summary: Successful antitumor immunity largely depends on efficient activation of T cells by antigen-presenting cells (APCs). However, APCs are found to be defective in many cancers. Cancer cells exploit nutrients in the tumor microenvironment (TME) to support their energy and biosynthetic demands, limiting the proper metabolic reprogramming of APCs. This review summarizes recent studies on the metabolic features of APCs and their functionality in the TME, and discusses the impact of cancer and immunomodulatory cell-derived metabolites on APCs.
Review
Immunology
Jaeoh Park, Pei -Chun Hsueh, Zhiyu Li, Ping-Chih Ho
Summary: Metabolic stress in the tumor microenvironment inhibits T cell anti-tumor immunity. Recent studies have identified strategies to activate T cell activities by targeting T cell metabolism, improving immune checkpoint blockade and adoptive cell transfer therapies. However, different treatment outcomes across cancers raise the question of universal understanding of CD8+ T cells in the tumor microenvironment, regardless of tissue origin.
Article
Dermatology
Chau Yee Ng, Yu-Pei Chan, Yen-Chuan Chiu, Han-Po Shih, You-Ning Lin, Pei-Han Chung, Jing-Yi Huang, Hung-Kai Chen, Wen-Hung Chung, Cheng-Lung Ku
Summary: This study aimed to investigate the direct toxicity of highly expressed cytokines in vitiligo skin lesions to melanocytes. The results showed that IFN-gamma can cause loss of melanocytes, increased oxidative stress, and disruption of melanogenesis. The use of anti-IFN-gamma monoclonal antibody may be a potential therapeutic option for vitiligo. In conclusion, this study confirms the direct toxicity effect of IFN-gamma on melanocytes in vitiligo skin and the potential utility of anti-IFN-gamma monoclonal antibody in treating vitiligo.
JOURNAL OF DERMATOLOGICAL SCIENCE
(2023)
Article
Immunology
Ana Garcia-Garcia, Rebeca Perez de Diego, Carlos Flores, Darawan Rinchai, Jordi Sole-Violan, Angela Deya-Martinez, Blanca Garcia-Solis, Jose M. Lorenzo-Salazar, Elisa Hernandez-Brito, Anna-Lisa Lanz, Leen Moens, Giorgia Bucciol, Mohamed Almuqamam, Joseph Domachowske, Elena Colino, Juan Luis Santos-Perez, Francisco Marco, Claudio Pignata, Aziz Bousfiha, Stuart Turvey, Stefanie Bauer, Filomeen Haerynck, Javier Gonzalo Ocejo-Vinyals, Francisco Lendinez, Seraina Prader, Nora Naumann-Bartsch, Jana Pachlopnik Schmid, Catherine Biggs, Kyla Hildebrand, Alexandra Dreesman, Miguel Angel Cardenes, Fatima Ailal, Ibtihal Benhsaien, Giuliana Giardino, Agueda Molina-Fuentes, Claudia Fortuny, Swetha Madhavarapu, Daniel Conway, Carolina Prando, Laire Schidlowski, Maria Teresa Martinez de Saavedra Alvarez, Rafael Alfaro, Felipe Rodriguez de Castro, Isabelle Meyts, Fabian Hauck, Anne Puel, Paul Bastard, Bertrand Boisson, Emmanuelle Jouanguy, Laurent Abel, Aurelie Cobat, Qian Zhang, Jean-Laurent Casanova, Laia Alsina, Carlos Rodriguez-Gallego
Summary: X-linked recessive deficiency of TLR7 impairs SARS-CoV-2 recognition and type I IFN production, resulting in hypoxemic COVID-19 pneumonia. 22 unvaccinated patients with autosomal recessive MyD88 or IRAK-4 deficiency were infected with SARS-CoV-2, with a high risk of severe pneumonia. Impaired TLR7-dependent type I IFN production contributes to their susceptibility to SARS-CoV-2.
JOURNAL OF EXPERIMENTAL MEDICINE
(2023)
Article
Genetics & Heredity
Daniela Matuozzo, Estelle Talouarn, Astrid Marchal, Peng Zhang, Jeremy Manry, Yoann Seeleuthner, Yu Zhang, Alexandre Bolze, Matthieu Chaldebas, Baptiste Milisavljevic, Adrian Gervais, Paul Bastard, Takaki Asano, Lucy Bizien, Federica Barzaghi, Hassan Abolhassani, Ahmad Abou Tayoun, Alessandro Aiuti, Ilad Alavi Darazam, Luis M. Allende, Rebeca Alonso-Arias, Andres Augusto Arias, Gokhan Aytekin, Peter Bergman, Simone Bondesan, Yenan T. Bryceson, Ingrid G. Bustos, Oscar Cabrera-Marante, Sheila Carcel, Paola Carrera, Giorgio Casari, Khalil Chaibi, Roger Colobran, Antonio Condino-Neto, Laura E. Covill, Ottavia M. Delmonte, Loubna El Zein, Carlos Flores, Peter K. Gregersen, Marta Gut, Filomeen Haerynck, Rabih Halwani, Selda Hancerli, Lennart Hammarstroem, Nevin Hatipoglu, Adem Karbuz, Sevgi Keles, Christele Kyheng, Rafael Leon-Lopez, Jose Luis Franco, Davood Mansouri, Javier Martinez-Picado, Ozge Metin Akcan, Isabelle Migeotte, Pierre-Emmanuel Morange, Guillaume Morelle, Andrea Martin-Nalda, Giuseppe Novelli, Antonio Novelli, Tayfun Ozcelik, Figen Palabiyik, Qiang Pan-Hammarstroem, Rebeca Perez de Diego, Laura Planas-Serra, Daniel E. Pleguezuelo, Carolina Prando, Aurora Pujol, Luis Felipe Reyes, Jacques G. Riviere, Carlos Rodriguez-Gallego, Julian Rojas, Patrizia Rovere-Querini, Agatha Schlueter, Mohammad Shahrooei, Ali Sobh, Pere Soler-Palacin, Yacine Tandjaoui-Lambiotte, Imran Tipu, Cristina Tresoldi, Jesus Troya, Diederik van de Beek, Mayana Zatz, Pawel Zawadzki, Saleh Zaid Al-Muhsen, Mohammed Faraj Alosaimi, Fahad M. Alsohime, Hagit Baris-Feldman, Manish J. Butte, Stefan N. Constantinescu, Megan A. Cooper, Clifton L. Dalgard, Jacques Fellay, James R. Heath, Yu-Lung Lau, Richard P. Lifton, Tom Maniatis, Trine H. Mogensen, Horst von Bernuth, Alban Lermine, Michel Vidaud, Anne Boland, Jean-Francois Deleuze, Robert Nussbaum, Amanda Kahn-Kirby, France Mentre, Sarah Tubiana, Guy Gorochov, Florence Tubach, Pierre Hausfater, C. O. V. I. D. Human Genetic Effort, Isabelle Meyts, Shen-Ying Zhang, Anne Puel, Luigi D. Notarangelo, Stephanie Boisson-Dupuis, Helen C. Su, Bertrand Boisson, Emmanuelle Jouanguy, Jean-Laurent Casanova, Qian Zhang, Laurent Abel, Aurelie Cobat
Summary: Through a genome-wide rare variant burden association analysis, it was found that there is an association between at-risk variants in the TLR7 gene and rare loss-of-function variants in TLR3-dependent type I interferon immunity genes. These findings suggest that rare variants in TLR3- and TLR7-dependent type I interferon immunity genes may underlie life-threatening COVID-19 in patients under 60 years old.
Article
Oncology
Yingxi Xu, Yi-Hsuan Chiang, Ping-Chih Ho, Nicola Vannini
Summary: This article gives an overview of the role of mitochondria in shaping the behavior of hematopoietic stem cells and T cells. It discusses the potential of novel mitochondria-targeting strategies for enhancing immunotherapies and emphasizes the need to consider the metabolic similarities and differences between these cell populations when designing and applying such approaches.
CANCER IMMUNOLOGY RESEARCH
(2023)
Article
Immunology
Fabien Franco, Alessio Bevilacqua, Ruey-Mei Wu, Kung-Chi Kao, Chun-Pu Lin, Lorene Rousseau, Fu-Ti Peng, Yu-Ming Chuang, Jhan-Jie Peng, Jaeoh Park, Yingxi Xu, Antonino Cassotta, Yi-Ru Yu, Daniel E. Speiser, Federica Sallusto, Ping-Chih Ho
Summary: Mitophagy plays a crucial role in the formation of memory CD8(+) T cells and T cell-mediated antiviral responses. Deficits in mitophagy lead to reduced frequency of CD8(+) memory T cells in Parkinson's disease patients and hinder the formation of memory T cells upon vaccination against COVID-19. Regulators of mitophagy, such as Parkin and NIX, are up-regulated by interleukin-15 (IL-15) to support memory T cell formation. Parkin suppresses apoptosis in memory T cells, while NIX prevents metabolic dysfunction and counteracts ferroptosis resulting from impaired mitophagy.
SCIENCE IMMUNOLOGY
(2023)
Review
Immunology
Giusy Di Conza, Ping-Chih Ho, Juan R. Cubillos-Ruiz, Stanley Ching-Cheng Huang
Summary: Initiating and maintaining optimal immune responses requires the endoplasmic reticulum's orchestration of protein synthesis and processing in leukocytes. Dysregulation of the unfolded protein response (UPR) in immune cells can lead to various pathologies. This review explores the role of UPR in immune cells and discusses how modulating this pathway could be used therapeutically.
NATURE REVIEWS IMMUNOLOGY
(2023)